Cargando…

Commentary on the NICE guideline on renal replacement therapy and conservative management

NICE Guideline NG107, “Renal replacement therapy and conservative management” (Renal replacement therapy and conservative management (NG107); 2018:1–33) was published in October 2018 and replaced the existing NICE guideline CG125, “Chronic Kidney Disease (Stage 5): peritoneal dialysis” (Chronic kidn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharbanda, Kunaal, Iyasere, Osasuyi, Caskey, Fergus, Marlais, Matko, Mitra, Sandip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379858/
https://www.ncbi.nlm.nih.gov/pubmed/34416872
http://dx.doi.org/10.1186/s12882-021-02461-4
_version_ 1783741094267191296
author Kharbanda, Kunaal
Iyasere, Osasuyi
Caskey, Fergus
Marlais, Matko
Mitra, Sandip
author_facet Kharbanda, Kunaal
Iyasere, Osasuyi
Caskey, Fergus
Marlais, Matko
Mitra, Sandip
author_sort Kharbanda, Kunaal
collection PubMed
description NICE Guideline NG107, “Renal replacement therapy and conservative management” (Renal replacement therapy and conservative management (NG107); 2018:1–33) was published in October 2018 and replaced the existing NICE guideline CG125, “Chronic Kidney Disease (Stage 5): peritoneal dialysis” (Chronic kidney disease (stage 5): peritoneal dialysis | Guidance | NICE; 2011) and NICE Technology Appraisal TA48, “Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure”(Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (Technology appraisal guideline TA48); 2002) The aim of the NICE guideline (NG107) was to provide guidance on renal replacement therapy (RRT), including dialysis, transplant and conservative care, for adults and children with CKD Stages 4 and 5. The guideline is extremely welcomed by the Renal Association and it offers huge value to patients, clinicians, commissioners and key stakeholders. It overlaps and enhances current guidance published by the Renal Association including “Haemodialysis” (Clinical practice guideline: Haemodialysis; 2019) which was updated in 2019 after the publication of the NICE guideline, “Peritoneal Dialysis in Adults and Children” (Clinical practice guideline: peritoneal Dialysis in adults and children; 2017) and “Planning, Initiation & withdrawal of Renal Replacement Therapy” (Clinical practice guideline: planning, initiation and withdrawal of renal replacement therapy; 2014) (at present there are no plans to update this guideline). There are several strengths to NICE guideline NG107 and we agree with and support the vast majority of recommendation statements in the guideline. This summary from the Renal Association discusses some of the key highlights, controversies, gaps in knowledge and challenges in implementation. Where there is disagreement with a NICE guideline statement, we have highlighted this and a new suggested statement has been written.
format Online
Article
Text
id pubmed-8379858
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83798582021-08-23 Commentary on the NICE guideline on renal replacement therapy and conservative management Kharbanda, Kunaal Iyasere, Osasuyi Caskey, Fergus Marlais, Matko Mitra, Sandip BMC Nephrol Guidelines NICE Guideline NG107, “Renal replacement therapy and conservative management” (Renal replacement therapy and conservative management (NG107); 2018:1–33) was published in October 2018 and replaced the existing NICE guideline CG125, “Chronic Kidney Disease (Stage 5): peritoneal dialysis” (Chronic kidney disease (stage 5): peritoneal dialysis | Guidance | NICE; 2011) and NICE Technology Appraisal TA48, “Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure”(Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (Technology appraisal guideline TA48); 2002) The aim of the NICE guideline (NG107) was to provide guidance on renal replacement therapy (RRT), including dialysis, transplant and conservative care, for adults and children with CKD Stages 4 and 5. The guideline is extremely welcomed by the Renal Association and it offers huge value to patients, clinicians, commissioners and key stakeholders. It overlaps and enhances current guidance published by the Renal Association including “Haemodialysis” (Clinical practice guideline: Haemodialysis; 2019) which was updated in 2019 after the publication of the NICE guideline, “Peritoneal Dialysis in Adults and Children” (Clinical practice guideline: peritoneal Dialysis in adults and children; 2017) and “Planning, Initiation & withdrawal of Renal Replacement Therapy” (Clinical practice guideline: planning, initiation and withdrawal of renal replacement therapy; 2014) (at present there are no plans to update this guideline). There are several strengths to NICE guideline NG107 and we agree with and support the vast majority of recommendation statements in the guideline. This summary from the Renal Association discusses some of the key highlights, controversies, gaps in knowledge and challenges in implementation. Where there is disagreement with a NICE guideline statement, we have highlighted this and a new suggested statement has been written. BioMed Central 2021-08-20 /pmc/articles/PMC8379858/ /pubmed/34416872 http://dx.doi.org/10.1186/s12882-021-02461-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Guidelines
Kharbanda, Kunaal
Iyasere, Osasuyi
Caskey, Fergus
Marlais, Matko
Mitra, Sandip
Commentary on the NICE guideline on renal replacement therapy and conservative management
title Commentary on the NICE guideline on renal replacement therapy and conservative management
title_full Commentary on the NICE guideline on renal replacement therapy and conservative management
title_fullStr Commentary on the NICE guideline on renal replacement therapy and conservative management
title_full_unstemmed Commentary on the NICE guideline on renal replacement therapy and conservative management
title_short Commentary on the NICE guideline on renal replacement therapy and conservative management
title_sort commentary on the nice guideline on renal replacement therapy and conservative management
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379858/
https://www.ncbi.nlm.nih.gov/pubmed/34416872
http://dx.doi.org/10.1186/s12882-021-02461-4
work_keys_str_mv AT kharbandakunaal commentaryontheniceguidelineonrenalreplacementtherapyandconservativemanagement
AT iyasereosasuyi commentaryontheniceguidelineonrenalreplacementtherapyandconservativemanagement
AT caskeyfergus commentaryontheniceguidelineonrenalreplacementtherapyandconservativemanagement
AT marlaismatko commentaryontheniceguidelineonrenalreplacementtherapyandconservativemanagement
AT mitrasandip commentaryontheniceguidelineonrenalreplacementtherapyandconservativemanagement